

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/091,567	03/07/2002	Jonathan P. Wong	NEL-006	7851
23353 7590 04/16/2008 RADER FISHMAN & GRAUER PLLC LION BUILDING			EXAMINER	
			HILL, MYRON G	
1233 20TH STREET N.W., SUITE 501 WASHINGTON, DC 20036		01	ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			04/16/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

	Application No.	Applicant(s)			
	10/091,567	WONG ET AL.			
	Examiner	Art Unit			
	MYRON G. HILL	1648			

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 16 January 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expires \_\_\_\_\_months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on 21 March 2008. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below);
(b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: \_\_\_\_\_. (See 37 CFR 1.116 and 41.33(a)). The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). Applicant's reply has overcome the following rejection(s): 112 first paragraph. 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. X For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) x will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 20-32. Claim(s) withdrawn from consideration: \_\_\_ AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: Note the attached Information Disclosure Statement(s), (PTO/SB/08) Paper No(s). 13. Other: See Continuation Sheet. /Bruce Campell/ /M. G. H./ Supervisory Patent Examiner, Art Unit 1648 Examiner, Art Unit 1648

U.S. Patent and Trademark Office

Continuation of 13. Other: In response to applicant's arguments and amendment, the 112 first paragraph rejectrion is withdrawn. The 103 rejection remains and is addressed as follows:

Applicant argues that Davis teaches away and teaches a different type of vaccine strategy and are not pertinant to applicant's endeavour, For the second 103, applicant argues that Webb et al. liposomes for cancer drug delivey and that the claimed liposomes have a longer half life than DOSPER liposomes.

Applicant's arguments have been fully considered and not found persuasive.

The Davis et al. reference does not teach away because immunizing to get an antibody response is known in the art and one of ordinary skill in the art at the time of invention would have known influenza and antibody responses to influenza. Also, Davis et al. does not teach away because the reference does not state that if you were to do the claimed invention it would fail.

As for Webb et al. applicants argument that it is not in the applicant's field of endeavour is not persuasive because that reference is not the basis of the rejection but is used to show that the ceramides uses in Wheeler et al. are available in different cohain structures and and that the different structures give different results. Also, there is no limitation in the claims either structural or functional that requires the vaccine (liopsomes to have a longer shelf life the DOPER.

Thus, the rejection is maintained.